BLFS
NASDAQ · Life Sciences Tools & Services
Biolife Solutions Inc
$18.85
-0.68 (-3.48%)
Financial Highlights (FY 2026)
Revenue
86.19M
Net Income
-21,148,757
Gross Margin
65.2%
Profit Margin
-24.5%
Rev Growth
-11.6%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 65.2% | 65.2% | 54.8% | 54.8% |
| Operating Margin | -8.7% | -7.8% | 5.1% | 5.3% |
| Profit Margin | -24.5% | -23.3% | 4.6% | 6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 86.19M | 97.54M | 1.26B | 1.01B |
| Gross Profit | 56.24M | 63.64M | 690.00M | 556.09M |
| Operating Income | -7,472,923 | -7,610,762 | 63.84M | 54.08M |
| Net Income | -21,148,757 | -21,538,849 | 58.21M | 63.51M |
| Gross Margin | 65.2% | 65.2% | 54.8% | 54.8% |
| Operating Margin | -8.7% | -7.8% | 5.1% | 5.3% |
| Profit Margin | -24.5% | -23.3% | 4.6% | 6.3% |
| Rev Growth | -11.6% | -11.6% | +9.5% | +17.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 24.23M | 24.23M | 538.01M | 550.42M |
| Total Equity | 530.19M | 530.19M | 666.68M | 636.38M |
| D/E Ratio | 0.05 | 0.05 | 0.81 | 0.86 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -4,083,964 | -4,390,365 | 80.62M | 66.64M |
| Free Cash Flow | — | — | 44.34M | 36.90M |